Table 1.
Vanderbilt Cohort Baseline Demographic Characteristics by rs6265 Genotype.
| Baseline Characteristics | All C/C (n=17) |
All C/T or T/T (n=11) |
DBS C/C (n=10) |
DBS C/T or T/T (n=5) |
MT C/C (n=7) |
MT C/T or T/T (n=6) |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Men | 14 | 11 | 9 | 5 | 5 | 6 |
| Women | 3 | 0 | 1 | 0 | 2 | 0 |
| Age (years) at enrollment | ||||||
| Mean | 61.2 (1.8) |
59.7 (1.5) |
60.4 (2.4) |
61.1 (1.9) |
62.2 (2.8) |
58.5 (2.4) |
| Range | 52.2 - 73.9 | 50.2 - 67.9 | 52.2 - 73.9 | 55.4 - 67.0 | 52.4 - 69.6 | 50.2 - 67.9 |
| PD Duration (years) | 2.2 (0.5) |
2.1 (0.6) |
2.6 (0.7) |
1.4 (0.7) |
1.7 (0.5) |
2.7 (0.9) |
| Medicine Use | ||||||
| Mean Duration (years) | 2.3 (0.4) |
1.8 (0.4) |
2.7 (0.7) |
1.5 (0.7) |
1.8 (0.3) |
2.1 (0.6) |
| Mean Levodopa equivalents, Total (mg/day) | 472.1 (73.2) |
427.6 (62.0) |
405.9 (100.5) |
469.7 (130.8) |
566.6 (102.6) |
392.5 (46.1) |
| From Levodopa and COMT inhibitors (mg/day) | 338.5 | 140.8 | 242.9 | 259.7 | 475.2 | 41.7 |
| From Dopamine agonists (mg/day) | 132.1 | 221.4 | 160.5 | 190.0 | 91.4 | 300.8 |
| From MAOB Inhibitors or antivirals (mg/day) | 1.5 | 65.4 | 2.5 | 20.0 | 0.0 | 50.0 |
| UPDRS Scores | ||||||
| Mean Total (ON) | 33.0 (3.9) |
37.7 (3.8) |
36.1 (5.4) |
34.2 (6.6) |
27.8 (5.1) |
40.6 (4.6) |
| Mean UPDRS I | 2.1 (0.4) |
1.5 (0.3) |
1.6 (0.5) |
1.8 (0.6) |
1.3 (0.4) |
2.3 (0.6) |
| Mean UPDRS II (OFF) | 11.2 (1.2) |
10.1 (1.3) |
13.1 (1.5) |
8.2 (1.5) |
8.4 (1.3) |
11.7 (1.5) |
| Mean UPDRS II (ON) | 8.2 (1.5) |
8.1 (1.1) |
9.3 (1.5) |
5.4 (1.9) |
6.3 (1.6) |
10.5 (1.8) |
| Mean UPDRS III (OFF) | 28.3 (2.3) |
30.6 (2.6) |
26.8 (3.3) |
30.2 (4.60 |
30.3 (3.3) |
30.8 (3.3) |
| Mean UPDRS III (ON) | 21.1 (2.9) |
25.2 (2.9) |
24.6 (6.0) |
23.2 (4.0) |
17.5 (4.2) |
25.7 (2.5) |
| Mean UPDRS IV | 2.0 (0.4) |
2.3 (0.8) |
2.0 (0.5) |
2.4 (1.3) |
2.0 (0.6) |
2.2 (1.0) |
MT = medical therapy, DBS = deep brain stimulation, COMT = catechol-O-methyltransferase, MAOB = monoamine oxidase B. Values represent the mean (SEM).